EOAI3402143 inhibits lung adenocarcinoma progression through the NF-κB/NR4A1 pathway

Lung adenocarcinoma (LUAD) is currently the cancer with the highest morbidity and mortality rates in the world, and its targeted therapy, although effective, is limited in the types of targeted drugs and prone to drug resistance in treated patients. Therefore, the continuous discovery of new targeted therapeutic agents is particularly crucial for the treatment of LUAD. Here, we aim to investigate the antitumor effect of EOAI3402143 on LUAD and the potential mechanism of its action. We use flow cytometry to analyze apoptosis, transwell and colony formation assays to detect cell migration, invasion and proliferation ability; western blot, RT-qPCR and RNA-seq to analyze the signaling pathways involved in EOAI3402143; and in vivo experiments to test the therapeutic effect of EOAI3402143 on LUAD. Our results show that EOAI3402143 promotes apoptosis and inhibits the migration, invasion and proliferation of LUAD cells. Mechanistic studies reveal that EOAI3402143 inhibits the activation of the NF-κB pathway and suppresses the expression of NR4A1, which in turn inhibits the progression of LUAD. In vivo experiments reveal that EOAI3402143 has a better therapeutic effect on LUAD. These findings indicate that EOAI3402143 has significant antitumor efficacy against LUAD and is promising as a new therapeutic agent for LUAD.